Broken pump or leaky filter? Renal dysfunction in heart failure a contemporary review

International Journal of Cardiology

Volumn 128, Issue 2, 2008, Pages 154-165

  Petrie, Colin J ^a   Mark, Partick B ^b   Weir, Robin A P ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Estimated glomerular filtration rate; Heart failure; Renal impairment; Survival

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ERYTHROPOIETIN; FLUINDOSTATIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; METOLAZONE; NESIRITIDE; PLACEBO; ROSUVASTATIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN;

ATHEROSCLEROSIS; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DRUG MECHANISM; DRUG MEGADOSE; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART FAILURE; HEMATURIA; HUMAN; HYPERKALEMIA; KIDNEY DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MORBIDITY; MORTALITY; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; REVIEW; RISK FACTOR; SIDE EFFECT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COMORBIDITY; DISEASE PROGRESSION; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; KIDNEY; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SURVIVAL RATE;

EID: 47749118388     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2007.12.016     Document Type: Review

References (113)

1. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 130 (1999) 461-470
2. Lin J., Knight E.L., Hogan M.L., et al. A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14 (2003) 2573-2580
3. O'Meara E., Chong K.S., Gardner R.S., et al. The Modification of Diet in Renal Disease (MDRD) equations provide valid estimations of glomerular filtration rates in patients with advanced heart failure. Eur J Heart Fail 8 1 (2006) 63-67
4. Smilde T.D., van Veldhuisen D.J., Navis G., et al. Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction. Circulation 114 (2007) 1572-1580
5. Levey A.S., Eckardt K.U., Tsukamoto Y., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 6 (June 2005) 2089-2100
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39 (2002) S1-S266
7. Griffin S.V., and MacGregor M.S. Facing an epidemic of chronic kidney disease. Clin Med 5 (2005) 521-525
8. Sarnak M.J., Levey A.S., Schoolwerth A.C., et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 42 (2003) 1050-1065
9. Tonelli, Wiebe N., Culleton B., et al. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol 17 (2006) 2034-2047
10. Foley R.N., Parfrey P.S., and Harnett J.D. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47 (1995) 186-193
11. Foley R.N., Perfrey P.S., and Harnett J.D. The prognostic importance of left ventricular geometry in uraemic cardiomyopathy. J Am Soc Nephrol 12 (1995) 2024-2031
12. Parfrey P.S., Foley R.N., and Harnett J.D. Outcome and risk factors for left ventricular disorders in chronic uraemia. Nephrol Dial Tansplant 11 (1996) 1277-1285
13. Hobson A., Kalra P.A., and Kalra P.R. Cardiology and nephrology: time for a more integrated approach to patient care?. Eur Heart J 23 (June 2005)
14. Ketler M., Schlieper G., and Floege J. Calcification and cardiovascular health: new insights in an old phenomenon. Hypertension 47 (2006) 1027-1034
15. Pannier B., Guèrin A.P., Marchais S.J., et al. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 45 (2005) 592-596
16. Hillege H.L., Fidler V., Diercks G.F.H., et al. Urinary albumin excretion predicts cardiovascular and non cardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
17. Schiffrin E.L., Lipman M.L., and Mann J.F.E. Chronic kidney disease. Effects on the cardiovascular system. Circulation 116 (2007) 85-97
18. Zoccali C., Bode-Boger S.M., Mallamaci F., et al. Plasma concentrations of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358 (2001) 2113-2117
19. Jofre R., Rodriguez-Benitez P., Lopez-Gomez J.M., et al. J Am Soc Nephrol 17 suppl 3 (2006) S274-S280
20. Elkayam U., Hatamizadeh P., and Janmohamed M. The challenge of correcting volume overload in hospitalized patients with decompensated heart failure. J Am Coll Cardiol 49 (2007) 684-686
21. Hillege H.L., Girbes A.R.J., de Kam P.J., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 (2000) 203-210
22. Smilde T.D.J., Hillege H.L., Navis G., et al. Impaired renal function in patients with ischaemic and non-ischaemic chronic heart failure: association with neurohormonal activation and survival. Am Heart J 148 (2004) 165-172
23. Smilde T.D.J., Hillege H.L., Voors A.A., et al. Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. Am J Cardiol 94 (2004) 240-243
24. Heywood J.T., Fonarow G.C., Costanzo M.R., et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Cardiac Fail 13 (2007) 422-430
25. Loegart D., Tabet J.Y., Hittinger L., et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol (2007) 10.1016/j.ijcard.2007.06.007
26. Forman D.E., Butler J., Wang Y., et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 43 (2004) 61-67
27. Van Kimmenade R.R., Januzzi Jr. J.L., Baggish A.L., et al. Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?. J Am Coll Cardiol 48 (2006) 1621-1627
28. Al Ahmad A., Rand W.M., Manjunath G., et al. Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38 (2001) 955-962
29. Knight E.L., Glynn R.J., McIntyre K.M., et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the Studies of Left Ventricular Dysfunction (SOLVD). Am Heart J 138 (1999) 849-855
30. Shlipak M.G., Smith G.L., Rathore S.S., et al. Renal function, digoxin therapy, and heart failure outcomes: evidence from the digoxin intervention group trial. J Am Soc Nephrol 15 (2004) 2195-2203
31. Aronson D., Mittleman M.A., and Burger A.J. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 116 (2004) 466-473
32. McClellan W.M., Flanders W.D., Langston R.D., et al. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: a population-based study. J Am Soc Nephrol 13 (2002) 1928-1936
33. Butler J., Forman D.E., Abraham W.T., et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 147 (2004) 331-338
34. Krumholz H.M., Chen Y.T., Vaccarino V., et al. Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol 85 (2000) 1110-1113
35. Adams Jr. K.F., Fonarow G.C., Emerman C.L., et al. ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 2 (Feb 2005) 209-216
36. Fonarow G.C., Adams Jr. K.F., Abraham W.T., et al. ADHERE Scientific Advisory Committee, Study Group, and Investigators. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293 5 (2005) 572-580
37. Shlipak M.S., and Massie B.M. The clinical challenge of cardiorenal syndrome. Circulation 110 (2004) 1514-1517
38. Anavekar N.S., McMurray J.J., Velazquez E.J., et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351 (2004) 1285-1295
39. Losito A., Errico R., Santirosi P., et al. Long-term follow up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition. Nephrol Dial Transplant 20 (2005) 1604-1609
40. Harding M.B., Smith L.R., Himmelstein S.I., et al. Renal artery stenosis: prevalence and associated risk factors in patients undergoing routine cardiac catheterization. J Am Soc Nephrol. 2 (1992) 1608-1616
41. Conlon P.J., O'Riordan E., and Kalra P.A. New insights into the epidemiologic and clinical manifestations of atherosclerotic renovascular disease. Am J Kidney Dis 35 (2000) 573-587
42. Gray B.H., Olin J.W., Childs M.B., et al. Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure. Vasc Med 7 (2002) 275-279
43. Missouris C.G., Belli A.M., and MacGregor G.A. "Apparent" heart failure: a syndrome caused by renal artery stenosis. Heart 83 (2000) 152-155
44. Missouris C.G., Buckenham T., Vallance P.J.T., et al. Renal artery stenosis masquerading as congestive heart failure. Lancet. 341 (1993) 1521-1522
45. Shah S.M.A., and Scoble J.E. 'Flash pulmonary oedema'-a diagnosis for both the cardiologist and the nephrologist?. Nephrol Dial Transplant 16 (2001) 1311-1313
46. Brammah A., Robertson S., Tait G., et al. Bilateral renovascular disease causing cardiorenal failure. Br Med J 326 (2003) 489-491
47. Bloch M.J., Trost D.W., Pickering T.G., et al. Prevention of recurrent pulmonary edema in patients with bilateral renovascular disease through renal artery stent placement. Am J Hypertens 12 (1999) 1-7
48. Ducloux D., Jamali M., and Chalopin J.M. Chronic congestive heart failure associated with bilateral renal artery stenosis. Clin Nephrol. 48 (1997) 54-55
49. Pickering T.G., Herman L., Devereux R.B., et al. Recurrent pulmonary oedema in hypertension due to bilateral renal artery stenosis: treatment by angioplasty or surgical revascularisation. Lancet 2 (1988) 551-552
50. Khosla S., White C.J., Collins T.J., et al. Effects of renal artery stent implantation in patients with renovascular hypertension presenting with unstable angina or congestive heart failure. Am J Cardiol 80 (1997) 363-366
51. Messina L.M., Zelenock G.B., Yao K.A., et al. Renal revascularization for recurrent pulmonary oedema in patients with poorly controlled hypertension and renal insufficiency: a distinct subgroup of patients with arteriosclerotic renal artery occlusive disease. J Vasc Surg 15 (1992) 73-80
52. Van Jaarsveld B.C., Krijnen P., Pieterman H., et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 342 (2000) 1007-1014
53. Mistry S., Ives N., Harding J., et al. Angioplasty and Stent for Renal Artery Lesions (ASTRAL trial): rationale, methods and results so far. J Hum Hypertens 21 (July 2007) 511-515
54. Weinfeld M.S., Chertow G.M., and Stevenson L.W. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J 138 (1999) 285-290
55. Philbin E.F., Cotto M., Rocco T., et al. Association between diuretic use,clinical response and death in acute heart failure. Am J Cardiol 80 4 (Aug 1997) 519-522
56. Lucas C., Johnson W., Hamilton M.A., et al. Freedom from congestion predicts good survival despite previous class IV symptoms of heart failure. Am Heart J 140 (2000) 840-847
57. Neuberg G.W., Miller A.B., O'Connor C.M., et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 144 (2002) 31-38
58. Shlipak M., Chertow G.C., and Massie B.M. Beware the rising creatinine level. J Card Fail 9 1 (2003) 26-27
59. Dormans T.P., van Meyel J.J., Gerlag P.G., et al. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 28 (1996) 376-382
60. Vermeulen A., and Chada D.R. Slow release furosemide and hydrochlorothiazide in congestive cardiac failure: a controlled trial. J Clin Pharmacol 22 (1982) 513-519
61. Pehrsson S.K. Multicentre comparison between slow-release furosemide and bendroflumethiazide in congestive heart failure. Eur J Clin Pharmacol 28 (1985) 235-239
62. Ljungman S., Laragh J.H., and Cody R.J. Role of the kidney in congestive heart failure-relationship of cardiac index to kidney function. Eur J Clin Pharmacol 28 (1985) 235-239
63. Damman K., Navis G., Smilde T.D.J., et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9 (2007) 872-878
64. Shlipak M.S. Pharmacotherapy for heart failure in patients with renal insufficiency. Ann Intern Med 138 (2003) 917-924
65. Granger C.B., McMurray J.J., Yusuf, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
66. Bakris G.L., and Weir M.R. Angiotensin-converting enzyme inhibition-associated elevations in serum creatinine. Is this a cause for concern?. Arch Intern Med 160 5 (2000) 685-693
67. Schoolwerth A.C., Sica D.A., Ballermann B.J., et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104 (2001) 1985-1991
68. Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
69. Anavekar N.S., Gans D.J., Berl T., et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for microalbuminuria. Kidney Int 66 Suppl 92 (2004) S50-S55
70. Brenner B.M., Cooper M.E., De Zeeuw, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
71. De Zeeuw D., Remuzzi G., Parving H.H., et al. Albuminuria, a therapeutic target for cardiovascular protection in type two diabetic patients with nephropathy. Circulation 110 (2004) 921-927
72. Chronic kidney disease is adults: UK guidelines for identification, management and referral. www.renal.org/CKDguide/ckd.html.
73. Solomon S.D., Rice M.M., Jablonski K.A., et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary artery disease in the prevention of events with ACE inhibition (PEACE) trial. Circulation 114 (2006) 26-31
74. Kittleson M., Hurwitz S., Shah M.R., et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 41 (2003) 2029-2035
75. Khan W., Deepak S.M., Coppinger T., et al. β-blocker treatment is associated with improvement in renal function and anemia in patients with heart failure. Heart 92 (2006) 1856-1857
76. Bakris G.L., Hart P., and Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int 70 (2006) 1905-1913
77. Cice G., Ferrara L., D'Andrea A., et al. Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy. J Am Coll Cardiol 41 (2003) 1438-1444
78. Hjalmarson A., Goldstein S., Fagerberg B., et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF study group. JAMA 283 (2000) 1295-1302
79. Erdmann E., Lechat P., Verkenne P., et al. Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 3 4 (2001) 469-479
80. Packer M., Fowler M.B., Roecker E.B., et al. Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106 17 (2002) 2194-2199
81. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
82. Pitt B., Remme W., Zannad F., et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
83. Sandhu S., Wiebe N., Fried L.F., et al. Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17 (2006) 2006-2016
84. Vid D.G., Cressman M.D., Harris S., et al. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 102 (2004) 52-60
85. Fellstro{double acute}m B., Abedini S., Holdaas H., et al. No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study. Clin Transplant 20 (2006) 732-739
86. Kjekshus J., Dunselman P., Blideskog M., et al. CORONA Study Group. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 6 (2005) 1059-1069
87. Silverberg D.S., Wexler D., and Iaina A. The importance of anaemia and its correction in the management of severe congestive heart failure. Eur J Heart Fail 4 (2002) 681-686
88. Ezekowitz J.A., McAlister F.A., and Armstrong P.W. Anemia is common in heart failure and is associated with poor outcomes. Circulation 107 (2003) 223-225
89. Parfrey P.S., Foley R.N., Wittreich B.H., et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 16 7 (2005) 2180-2189
90. Besarab A., Kline Bolton W., Browne J.K., et al. The effects of normal as compared with low haematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339 (1998) 584-590
91. Drüeke T.B., Locatelli F., Clyne N., et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355 (2006) 2071-2084
92. Singh A.K., Szczech L., Tang K.L., et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355 (2006) 2085-2098
93. Go A.S., Yang J., Ackerson L.M., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure. Circulation 113 (2006) 2713-2723
94. Van Veldhuisen D.J., Dickstein K., Cohen-Solal A., et al. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbopoetin alfa in patients with heart failure and anaemia (August 6th 2007) 10.1093/eurheartj/ehm328
95. Van Veldhuisen D.J., and McMurray J.J.V. on behalf of the RED-HF Executive Committee. Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need and adequately powered randomized trial. Eur J Heart Fail 9 (2007) 110-112
96. Wang D.J., Dowling T.C., Meadows D., et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation 110 (2004) 1620-1625
97. Sackner-Bernstein J.D., Skopicki H.A., and Aaronson K.D. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 111 (2005) 1487-1491
98. Gottlieb S.S., Brater D.C., Thomas I., et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105 (2002) 1348-1353
99. Francis G.S., Benedict C., Johnstone D.E., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure: a substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 82 (1990) 1724-1729
100. Gheorhiade M., Gattis W.A., O'Connor C.M., et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalised with worsening heart failure. A Randomized Controlled Trial. JAMA 291 (2004) 1963-1971
101. Konstam M.A., Gheorghiade M., Burnett Jr. J.C., et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 12 (2007) 1319-1331
102. Costanzo M.R., Guglin M.E., Saltzberg M.T., et al. Ultrafiltration versus intravenous diuretics for patients hospitalised for acute decompensated heart failure. J Am Coll Cardiol 49 (2007) 675-683
103. Domingo K.B., Lin F., Vittinghoff E., et al. Renal insufficiency as an independent predictor of mortality among women with heart failure. J Am Coll Cardiol 44 (2004) 1593-1600
104. Hillege H.L., Nitcsh D., Pfeffer M.A., et al. Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation. 113 (2006) 671-678
105. Mahon N.G., Blackstone E.H., Francis G.S., et al. The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 40 6 (2002) 1106-1113
106. Rudiger A., Harjola V.P., Müller A., et al. Acute heart failure: clinical presentation, one year mortality and prognostic factors. Eur J Heart failure 7 (2005) 662-670
107. Akhter M.W., Aronson D., Bitar F., et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 94 7 (2004) 957-960
108. Felker G.M., Leimberger J.D., Califf RM, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail 10 6 (2004) 460-466
109. McAlister F.A., Ezekowitz J., Tonelli M., et al. Renal insufficiency and heart failure. Prognostic and therapeutic implications from a prospective cohort study. Circulation 109 (2004) 1004-1009
110. Tavazzi L., Naggioni A.P., Lucci D., et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 27 10 (2006) 1207-1215
111. Cowie M.R., Wood D.A., Coats A.J., et al. Survival of patients with a new diagnosis of heart failure: a population based study. Heart 83 5 (2000) 505-510
112. Bouvy M.L., Heerdink E.R., Leufkens H.G., et al. Predicting mortality in patients with heart failure: a pragmatic approach. Heart 89 6 (2003) 605-609
113. Berry C., Hogg K., Norrie J., et al. Heart failure with preserved left ventricular systolic function: a hospital cohort study. Heart 91 7 (2005) 907-913